2024-07-03 03:11:04 ET
Summary
- Caribou Biosciences develops allogeneic therapies using CRISPR technology, focusing on hematologic cancers and autoimmune diseases.
- CB-010, CB-011, and CB-012 are in Phase 1 clinical trials, with CB-010 showing promising results for B cell non-Hodgkin lymphoma.
- Evercore downgraded CRBU’s stock due to high COGS concerns, but its superior efficacy and safety might justify higher prices.
- CRBU’s CB-010 achieved a 92% ORR and favorable safety compared to competitors Yescarta and Kymriah.
- Despite early-stage risks, CRBU’s undervaluation and large TAM present a compelling speculative buy opportunity.
Read the full article on Seeking Alpha
For further details see:
Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential